Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 1 1

Status

Terminated 3Completed 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Lymphoma, Non-Hodgkin 5Recurrence 2

Interventions

Rituximab 130Cyclophosphamide 41Bendamustine Hydrochloride 39venetoclax 25fludarabine 25obinutuzumab 24Lenalidomide 23ibrutinib 22Gemcitabine 22Vincristine 20Prednisone 20tositumomab I-131 19Doxorubicin 19plerixafor 14Dexamethasone 14Granulocyte Colony-Stimulating Factor 12pirtobrutinib 11Brentuximab Vedotin 11glofitamab 10tocilizumab 9pembrolizumab 9ibritumomab tiuxetan 9Etoposide 9Azacitidine 9polatuzumab vedotin 8parsaclisib 8copanlisib 8acalabrutinib 8Drug Therapy 8ublituximab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Non-Hodgkin × galiximab × Clear all
NCT00384150 2015-11-26

Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)

Biogen

Phase 3 Terminated
16 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT00363636 2015-10-02

A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)

Biogen

Phase 3 Terminated
340 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT00048555 2013-09-16

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

Biogen

Phase 1/2 Completed
90 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT00575068 2012-06-08

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Biogen

Phase 1/2 Completed
42 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT00651443 2011-01-07

Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma

Biogen

Phase 1 Terminated
20 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡